304 related articles for article (PubMed ID: 21344445)
1. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Karnezis TT; Davidson TM
Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
[TBL] [Abstract][Full Text] [Related]
2. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
Chen S; Karnezis T; Davidson TM
Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.
Karnezis TT; Davidson TM
Laryngoscope; 2012 Mar; 122(3):495-7. PubMed ID: 22147664
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
[TBL] [Abstract][Full Text] [Related]
5. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
Simonds J; Miller F; Mandel J; Davidson TM
Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
[TBL] [Abstract][Full Text] [Related]
6. Hereditary hemorrhagic telangiectasia/avastin.
Davidson TM; Olitsky SE; Wei JL
Laryngoscope; 2010 Feb; 120(2):432-5. PubMed ID: 19998344
[TBL] [Abstract][Full Text] [Related]
7. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.
Guldmann R; Dupret A; Nivoix Y; Schultz P; Debry C
Laryngoscope; 2012 May; 122(5):953-5. PubMed ID: 22447341
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
Rohrmeier C; Sachs HG; Kuehnel TS
Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
[TBL] [Abstract][Full Text] [Related]
10. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
[TBL] [Abstract][Full Text] [Related]
11. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.
Alderman C; Corlett J; Cullis J
Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440
[No Abstract] [Full Text] [Related]
12. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
[TBL] [Abstract][Full Text] [Related]
13. Long-term experience with intranasal bevacizumab therapy.
Steineger J; Osnes T; Heimdal K; Dheyauldeen S
Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
[TBL] [Abstract][Full Text] [Related]
14. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
15. Avastin and diode laser: a combined modality in managing epistaxis in hereditary hemorrhagic telangiectasia.
Marglani OA; Bawazeer NA; Abu Suliman OA
Am J Otolaryngol; 2013; 34(5):603-5. PubMed ID: 23541684
[TBL] [Abstract][Full Text] [Related]
16. Intranasal bevacizumab injections improve quality of life in HHT patients.
Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.
Steineger J; Merckoll E; Slåstad JM; Eriksen EF; Heimdal K; Dheyauldeen S
Laryngoscope; 2018 Mar; 128(3):593-596. PubMed ID: 28671294
[TBL] [Abstract][Full Text] [Related]
18. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis.
Harvey RJ; Kanagalingam J; Lund VJ
Am J Rhinol; 2008; 22(2):182-7. PubMed ID: 18416977
[TBL] [Abstract][Full Text] [Related]
19. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
Stokes P; Rimmer J
Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
[TBL] [Abstract][Full Text] [Related]
20. Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis.
Luk L; Mace JC; Bhandarkar ND; Sautter NB
Int Forum Allergy Rhinol; 2014 Aug; 4(8):640-5. PubMed ID: 24719397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
